The DRG1 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the human DRG1 gene in the HAP1 cell line. As a polyclonal knockout pool, this product consists of a heterogeneous mixture of cells carrying diverse CRISPR/Cas9-induced mutations at the DRG1 locus, providing a robust loss-of-function model that circumvents clonal artifacts and epigenetic drift. The polyclonal format ensures that the observed phenotype reflects the consensus effect of DRG1 loss across multiple independent editing events, making it particularly suitable for functional genomics screens where reproducibility and biological variability are critical. This ready-to-use knockout population is delivered as a validated pool, enabling immediate application in downstream cellular assays without the need for single-cell cloning.
The host HAP1 cell line is a near-haploid human cell line originally derived from KBM-7 chronic myeloid leukemia cells. Its haploid nature simplifies the study of gene function, as most genes exist in a single copy, eliminating the need for homozygous knockout generation and reducing compensatory effects from secondary alleles. HAP1 cells are widely employed in haploid genetic screens, CRISPR-based knockout studies, and drug discovery pipelines due to their stable karyotype and ease of genetic manipulation. The chronic myeloid leukemia origin of HAP1 provides a relevant background for investigating cancer-related pathways, including those governing ribosome biogenesis and translational control, which are often dysregulated in leukemogenesis.
DRG1 (developmentally regulated GTP-binding protein 1) encodes a highly conserved GTPase that plays an essential role in ribosome maturation and cell cycle progression. DRG1 functions downstream of mTORC1 kinase, a central nutrient sensor, and is activated by growth factor signaling, integrating external stimuli with the cellular translational machinery. At the molecular level, DRG1 interacts with key ribosomal RNA processing factors and cell cycle regulators, and forms complexes with proteins such as TAF12, ZFAND3, and DFRP1. Within the mTOR signaling axis, DRG1 operates in concert with S6K and TIF-IA to modulate RNA polymerase I activity and promote ribosomal RNA synthesis, thereby linking nutrient availability to ribosome biogenesis and protein synthesis. This GTPase thereby serves as a critical junction between metabolic cues and the anabolic machinery driving cell growth and proliferation.
In the HAP1 cellular context, the near-haploid genome uniquely potentiates the utility of a DRG1 knockout model. Because HAP1 cells harbor only one copy of most genes, including DRG1, the introduction of a single disruptive edit effectively ablates gene function without the confounding influence of a wild-type allele. This genetic simplicity renders the DRG1 Knockout HAP1 Polyclonal Cells an incisive tool for delineating the direct consequences of DRG1 loss on ribosome assembly, mTOR signaling dynamics, and cell cycle regulation. Moreover, the leukemic background of HAP1 cells provides a disease-relevant platform for exploring the role of DRG1 in cancer cell biology, particularly in contexts where mTOR hyperactivity drives aberrant ribosome biogenesis and unchecked proliferation.
The DRG1 Knockout HAP1 Polyclonal Cells are ideally suited for a broad spectrum of research applications, including functional genomics, ribosome biogenesis studies, and drug target validation. Experimentally, this loss-of-function model can be utilized in cell proliferation assays to assess growth dependency, ribosome profiling to map changes in translational landscapes, and western blotting to monitor ribosomal protein expression or mTOR pathway markers under DRG1 depletion. Transcriptomic analysis via RNA-seq can further reveal alterations in gene expression programs governed by DRG1. Researchers investigating the mTOR signaling pathway, the translational control of oncogenic programs, or the molecular vulnerabilities of leukemia cells will find this knockout population to be a valuable resource. For further information, please contact Ascent Research.
